SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (2723)5/2/2011 9:20:40 AM
From: richardred  Respond to of 7254
 
Merger Monday and I suspect VRX will be on the prowl after being left on the altar by Cephalon.

Teva to Buy Cephalon for $6.8 Billion

more in Health »
BY MATT JARZEMSKY

Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion, building its branded and specialty pharmaceuticals business as it seeks growth to meet its 2015 revenue targets.

Cephalon shares rose 5.5% to $81.25 in premarket trading, compared with the $81.50 offer price. Teva's American depositary shares climbed 3.4% to $47.30.
online.wsj.com